Ozempic and Your Knees: The NEJM Trial That Cut Knee OA Pain Nearly in Half

Semaglutide roughly doubled knee OA pain relief vs placebo — and some GLP-1 users ache MORE. Both halves, honestly.

The biggest drug story of the decade now has a knee-arthritis chapter, and it's a genuinely strong one: in the STEP 9 randomized trial (published in the New England Journal of Medicine), semaglutide roughly doubled knee osteoarthritis pain relief versus placebo — a ~29-point drop on the WOMAC pain scale versus ~14 — alongside 13.7% body-weight loss over 68 weeks. For a condition whose drug options have barely moved in decades, that's a landmark result. It also comes with honest fine print, including the counter-story nobody warns people about: some GLP-1 users report more aches, not fewer. Both halves below.

What the trial actually showed

STEP 9 enrolled 407 people with obesity and painful knee OA and randomized them to weekly semaglutide (the drug in Ozempic/Wegovy) or placebo, both alongside lifestyle counseling. At 68 weeks, the semaglutide group had lost 13.7% of body weight (vs 3.2%) and reported dramatically larger pain improvements — the kind of effect size knee OA trials essentially never produce. A systematic review of GLP-1 agonists in knee OA points the same direction across the emerging evidence.

Why it works is mostly not mysterious: every pound of body weight puts several pounds of force through the knee per step, so 14% weight loss is a massive mechanical unloading — the weight lever this site has called diet's most powerful joint effect, delivered pharmacologically. There's also a plausible bonus: GLP-1 drugs appear to reduce systemic inflammation somewhat, and researchers are actively probing whether there's a joint benefit beyond the scale. That part is unproven; the unloading is physics.

The honest fine print

• Not approved for arthritis. Semaglutide is approved for diabetes and weight management; knee OA benefit rode along in a population with obesity. If you're not in that population, this trial says little about you.
• It treats the load, not the disease. Cartilage doesn't regrow on semaglutide — OA remains managed, not reversed. Stop the drug, regain the weight, and the mechanical math returns.
• The counter-story is real: "Ozempic made me achy." Rapid weight loss can take muscle along with fat — and muscle is the joint's shock absorber. Users who lose lean mass quickly, eat too little protein, and don't strength-train can end up with less-protected joints and new aches, plus the fatigue that under-fueling brings. The fix is known: resistance training and adequate protein are now standard advice alongside GLP-1s — for your joints as much as your physique.
• Cost, access, side effects (GI effects lead the list) are their own real conversation — with a doctor, not a blog.

What to do with this

If you have knee OA and significant weight to lose, STEP 9 makes GLP-1s a legitimate question for your doctor — framed exactly that way, since candidacy, alternatives (structured weight-loss programs achieve smaller but real unloading too), and long-term planning are clinical judgments. If you're already on one: lift something a couple of times a week, keep protein up, and log your joint symptoms through the weight change — Flare's weather-paired record will show you what the unloading is actually buying your knees, separate from what the seasons are doing. Many users find the trendline is the most motivating chart they own.

FAQ

Does Ozempic actually help knee arthritis?

In the STEP 9 trial, semaglutide roughly doubled knee OA pain relief vs placebo in people with obesity — driven largely by 13.7% weight loss unloading the joint.

Is it approved for arthritis?

No — approved for diabetes and weight management; the knee benefit is a documented effect in that population, not an OA indication.

Why do some people ache more on GLP-1s?

Rapid weight loss can cost muscle — the joint's protection — especially without strength training and protein. The aches are usually the fix-it kind.

Should I ask my doctor about it?

If knee OA and meaningful excess weight coexist for you, yes — it's now a legitimate, evidence-backed question, with candidacy and trade-offs being theirs to weigh with you.

Sources

STEP 9 trial — semaglutide in knee osteoarthritis, NEJM (PubMed) · Systematic review — GLP-1 receptor agonists and knee OA · NIAMS (NIH) — Arthritis overview · Cleveland Clinic — Arthritis

This article is for informational purposes only and is not medical advice. GLP-1 medications require prescription and medical supervision — all decisions belong with your doctor.